Product logins

Find logins to all Clarivate products below.


Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant discomfort. (The treatment of acute flares is distinct from that of chronic gout and is not the focus of this analysis.) Chronic treatment aims to avert recurrent gout attacks and prevent joint damage by reducing sUA levels. Xanthine oxidase inhibitors (XOIs), especially the widely prescribed generic allopurinol, form the cornerstone of chronic gout treatment. For later lines of therapy, Krystexxa, a highly efficacious biological drug, is used. This report offers valuable insight into the application of these treatments in patients newly diagnosed with or recently treated for chronic gout.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed gout patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed gout patients?
  • How has Krystexxa been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of gout patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of gout patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key drugs: Allopurinol, Febuxostat, Krystexxa, Probenecid

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Breast Cancer | China In-Depth | China | 2024
The breast cancer therapy market is one of the most dynamic markets in the oncology space in mainland China. Several new and emerging therapies are set to be approved for select subpopulations;…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Diabetic macular edema (DME), a complication of diabetic retinopathy (DR), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left…
Report
Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast (G7)
Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are…
Report
Systemic Lupus Erythematosus – Landscape & Forecast – Disease Landscape & Forecast (G7)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment can be highly…
Report
Type 2 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
The type 2 diabetes (T2D) therapy market will expand through 2034, supported by polypharmacy and the growing use of effective branded therapies offering nonglycemic benefits. Although the loss of…